David ,if you thought I was talking about you I surely was not, you are one of many smart people that did the DD , that knows what we have here , and this PR is not fluff we are rubbing shoulder with a major part of the Federal Government the USDA ,WOW, these are exciting time for the company and it's shares holders , that song comes to mind [don't worry be happy] .
CytoGenix and USDA to Collaborate in Developing a synDNA(TM) Vaccine Against Costly Livestock Disease
Monday May 8, 9:15 am ET
HOUSTON--(BUSINESS WIRE)--May 8, 2006--CytoGenix, Inc. (OTCBB:CYGX - News) announced that it has entered into a formal Cooperative Research and Development Agreement (CRADA) with the USDA Agricultural Research Service.
ADVERTISEMENT
CytoGenix scientists will work with a team of USDA scientists led by Dr. Steven Olsen to develop synDNA(TM) vaccines against existing and emerging strains of the bacteria that causes brucellosis, a costly disease for ranchers and game managers. Brucellosis causes miscarriages in domestic sheep, goats, cattle, pigs, and in wildlife such as deer, elk and bison. State and Federal governments have spent $11 billion over the last 45 years in an attempt to eradicate this disease.
Dr. Olsen, Director of Vaccine Research for the Agricultural Research Service, USDA commented, "There remain reservoirs of brucella in wildlife within Yellowstone Park, and the potential for brucellosis infection is a serious threat to cattle ranchers in the region. For this reason, ARS has been conducting research to develop DNA vaccines for brucella infections for several years."
Dr. Malcolm Skolnick, CytoGenix Chief Executive Officer, commented, "We are pleased to be working with Dr. Olsen and his team of scientists at USDA. ARS is a leader within the Federal government in the transferal and marketing of new technologies developed from its research laboratories. This CRADA is another example of our commitment to exploring the utility of synDNA(TM) technology in cooperation with governmental agencies."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology
News 
Market Data 
Discover 
AI
